National Beverage Corp., through its subsidiaries, develops, produces, markets, and sells a portfolio of sparkling waters, juices, energy drinks, and carbonated soft drinks in the United States and Canada.
FAIL · Does not pass the screen
37.16 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price37.16 USD at the 5 Nov 2026 close
Fair value26.82. Our model only; only one analyst covers it, too few to cross-check it.
Our value readOvervalued vs our fair value, as of 5 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.00, read 2026-11-03
Ethical does not pass the values gate
Price37.16 USD
Fair value26.82Our model only; only one analyst covers it, too few to cross-check it.
Ethical score30.0/100
Value readOvervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-11Read Markup30.65+21.2% to today ✓Distribution gives way to Markup
2026-10-02Read Distribution30.65+21.2% to today Accumulation gives way to Distribution
2026-09-05Read Accumulation32.24+15.3% to today ✓Markdown gives way to Accumulation
2026-09-03Read Markdown31.48+18.0% to today Accumulation gives way to Markdown after a 15% slide in 9 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
National Beverage Corp. holds its Markup at $37.16. Consolidating, no directional conviction, held for 56 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 56 days
Price at the screen
$37.16
Valuation
18.80 trailing · 17.88 forward price to earnings
Values screen
FAIL· score 30.0
Beta
0.85
The Workings
Five Screens, Shown in Full
Does not pass. Prohibited keyword in sector/industry: alcohol
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Prohibited keyword in sector/industry: alcohol
Fail
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
Excluded
Below 33%
Interest-bearing cash and securities are of assets, above the one-third limit.
Fail
Receivables
Excluded
Below 49%
Money owed to the company is of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
National Beverage does not clear the screen at the business-activity stage. It operates in alcohol, so the financial ratios are not the deciding factor here.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when FIZZ's ethical verdict changes
Today FIZZ does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our model only; only one analyst covers it, too few to cross-check it.
Our analysis reads Overvalued vs our fair value, as of 5 Nov 2026: it trades above our $26.82 fair value estimate.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. The price runs 38.6% above the base estimate.
Reading the gap · Both our model and the Street see limited upside at this price.
Where our models see it going: fair-value estimate $26.82, with a range of $26.82 to $30.84, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
National Beverage trips the ethical screen hard
Every time a shopper reaches for a sparkling water or energy drink at the corner store, the transaction looks simple enough. National Beverage runs the operation behind those shelves, yet the business fails our ethical screen outright because of a prohibited alcohol link in its sector. That single red flag ends any further look.
The numbers do not help the case either. Revenue is already shrinking 5 percent, the shares trade above our fair value with negative margin of safety, and only one analyst even bothers with a sell rating. High ROE of 34 percent cannot mask the absence of growth or the ethical block.
Risk sits in plain sight: once an ethical screen is triggered there is no workaround, and the weak top-line trend only adds to the reasons to stay away. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
FIZZ trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Markup$35.30+7.0%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (1 analysts) rates it none, with a mean price target of $35.
2026-10-25Markup$32.99+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (1 analysts) rates it none, with a mean price target of $35.
2026-10-18Markup$32.99+7.6%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (1 analysts) rates it none, with a mean price target of $35.
2026-10-11Markup · changed$30.65+0.0%Entry 14
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (1 analysts) rates it none, with a mean price target of $35.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (1 analysts) rates it none, with a mean price target of $35.
2026-09-10Accumulation$32.24+0.0%Entry 12
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (1 analysts) rates it none, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-09Accumulation$32.24+0.0%Entry 11
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (1 analysts) rates it none, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-08Accumulation$32.24+0.0%Entry 10
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (1 analysts) rates it none, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-06Accumulation$32.24+0.0%Entry 9
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (1 analysts) rates it none, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (1 analysts) rates it none, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
